Literature DB >> 3132790

Exaggerated growth hormone response to growth hormone-releasing hormone in type I diabetes mellitus.

J Krassowski1, J P Felber, H Rogala, W Jeske, S Zgliczynski.   

Abstract

Excessive GH response to various stimuli has been frequently described in diabetes mellitus. We studied the GH response to a synthetic GHRH in a group of 16 non-obese Type I diabetic patients. GHRH (1-44) given as iv bolus at a dose of 50 micrograms induced a markedly greater GH response in the diabetic than in the normal subjects with peak values of 39.5 and 14.7 micrograms/l, respectively, and the differences were significant from 15 to 60 min. Peak GH level was 44.6 micrograms/l in diabetic patients without retinopathy and 34.2 micrograms/l in patients with retinopathy, but the difference was not significant. Peak GH levels did not correlate with metabolic control of disease estimated by basal glucose and HbA1 levels nor with age, weight of the patients, and duration of the disease. It is concluded that Type I diabetic patients show an exaggerated GH response to GHRH and this response does not correlate with the metabolic control of diabetes.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3132790     DOI: 10.1530/acta.0.1170225

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  7 in total

1.  Clinical and pharmacological characterization of anomalous metoclopramide-induced growth hormone secretion in insulin-dependent diabetes mellitus.

Authors:  F Caviezel; G Lepore; M L Maglio; M Croci; G Comi; L Morricone
Journal:  Acta Diabetol Lat       Date:  1989 Apr-Jun

2.  Inappropriate growth-hormone (GH) response to thyrotropin-releasing hormone (TRH) occurs infrequently in well-regulated diabetes mellitus.

Authors:  O Giampietro; M Ferdeghini; R Miccoli; G Gregori; G Penno; S Bertoli; R Navalesi
Journal:  Acta Diabetol Lat       Date:  1990 Apr-Jun

Review 3.  The glomerular podocyte as a target of growth hormone action: implications for the pathogenesis of diabetic nephropathy.

Authors:  P Anil Kumar; Frank C Brosius; Ram K Menon
Journal:  Curr Diabetes Rev       Date:  2011-01

4.  The effects of a specific growth hormone antagonist on overnight insulin requirements and insulin sensitivity in young adults with Type 1 diabetes mellitus.

Authors:  R M Williams; R Amin; F Shojaee-Moradie; A M Umpleby; C L Acerini; D B Dunger
Journal:  Diabetologia       Date:  2003-07-24       Impact factor: 10.122

Review 5.  Involvement of brain catecholamines and acetylcholine in growth hormone hypersecretory states. Pathophysiological, diagnostic and therapeutic implications.

Authors:  E E Müller; M Rolla; E Ghigo; D Belliti; E Arvat; A Andreoni; A Torsello; V Locatelli; F Camanni
Journal:  Drugs       Date:  1995-11       Impact factor: 9.546

6.  Variability in the growth hormone response to growth hormone-releasing hormone alone or combined with pyridostigmine in type 1 diabetic patients.

Authors:  A Giustina; C Bodini; S Bossoni; U Valentini; W B Wehrenberg
Journal:  J Endocrinol Invest       Date:  1993-09       Impact factor: 4.256

7.  Somatomedin-C (SM-C). Study in diabetic patients with and without retinopathy.

Authors:  G M Nardelli; E Guastamacchia; S Di Paolo; A Balice; M Rosco; G Santoro; G Lollino; R Giorgino
Journal:  Acta Diabetol Lat       Date:  1989 Jul-Sep
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.